Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces activity at the following scientific and investor conferences during April 2024. Read more…
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American […]
London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]
More than hangover-busting aspirin will be in order at the biopharma industry’s biggest week in London. The capital will host a gruelling conference double header, beginning with the LSX Inv€$tival Showcase on Monday 13th November, followed by the Jefferies London Healthcare Conference on Tuesday 14th November. With investors and biopharma business leaders descending on the […]
Geneva, Switzerland and Amsterdam, The Netherlands, 1 June 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023. Read more…
